UNH at $325: You're Paying Fair Value for UnitedHealthcare and Getting Optum at 4x

UnitedHealth is the biggest holding in the S&P 500 healthcare ETF that almost nobody wants to own right now. The stock is down roughly 50% from its 2024 highs and still −7% year-to-date after a double-digit rally on the April 6 CMS rate announcement. At Friday's $325 against a $494 sum-of-parts, the cheapness is already obvious. The interesting question isn't is it cheap. The interesting question is what the market is pricing in that we're not.

Our answer, in one sentence: at Friday's $325 you're buying UnitedHealthcare at roughly fair value and getting all of Optum at about four times operating earnings. The rest of this post explains why we think that asymmetry exists, when it closes, and what has to go right — or wrong — for the thesis to hold.

On pricing. This post publishes Sunday, April 19. We don't know Monday's open, and we wouldn't dignify citing Friday's close as our entry price — readers can't transact against a price the weekend sits on top of. Our model-portfolio position will open at Monday's close, April 20, after this thesis has been publicly available for a full trading session. All price-point claims in this post reference Friday's close as the snapshot we analyzed; the actual execution price and resulting payoff ratio will be set by Monday's market, not by our framing.

The sector hook

One sector data point matters for this thesis: CMS announced a +2.48% 2027 Medicare Advantage rate on April 6, above expectations, delivering an estimated $13B of incremental payments across private insurers. UNH rallied +10.4% that day; Humana +12.6%; CVS +7.8%. The rate is a clean positive for the insurance-side earnings trajectory and supports management's 2026 EPS floor above $17.75.

The next data point is April 21 — UNH Q1 2026 earnings. This is the first earnings-level test of whether the turnaround is actually converting and, specifically, whether the medical care ratio (MCR) is stabilizing. An MCR print below 89% accelerates the thesis. Above 89.5% resets it. Everything else in the print is secondary.

For the broader sector context — tariff architecture, patent-cliff M&A, oncology readouts — see our weekly healthcare sector briefing (PDF, April 19 2026). Those themes affect most of XLV. UNH is notable for being mostly insulated from them (it's a domestic services business, not an importer or drug franchise).

What UNH actually is

Four distinct businesses under one holding company, with the segment mix shown below:

Bridge to equity: $552B segment EV − $78B corporate debt + $24B corporate cash = $498B pre-discount equity = $549/share on 907.7M shares. Apply our 10% conglomerate discount → $448B equity / $494 per share.

A note on history before the segment math: Optum was formed in 2011 by combining UNH's existing pharmacy and care-delivery businesses. It is not a recently-assembled conglomerate bolted together for empire-building; it is 15 years of operational integration, $173B of intersegment revenue in 2025, and a shared clinical-data layer. That history matters for the discount argument below.

The core reframe: UHC at fair value, Optum at 4x

This is the cleanest way to see the mispricing.

UHC by itself, per our DCF at a 7.24% WACC and a 88.5% terminal MCR, supports $273.5B of segment EV. Allocating corporate net debt (\~$54B) pro-rata to segment weight, UHC's share of equity is \~$246B, or $271 per share. That is UHC alone — the insurance business that printed $9.4B of earnings in 2025 and guides to $10.8B+ in 2026 (3.2% operating margin, expanding from 2.7%).

At Friday's $325, you are paying \~$54/share above UHC-alone. On 907.7M shares, that's $49B of equity value — about $103B of enterprise value after debt adjustment — for all three Optum segments combined. Which produced:

• Optum Rx: $154.7B revenue, $6.1B adj OI, 1.66B adjusted scripts (2025)
• Optum Insight: $19.4B revenue, $3.7B adj OI, 21.7% adjusted margin on the recast basis (2025)
• Optum Health: $102.0B revenue, $2.3B adj OI in a crisis year (2025)

Total Optum adjusted OI 2025: $12.1B. Management's 2026 guide: $13.2B.

The market is paying roughly 4x current-year Optum adjusted OI. PBM peers (Cigna's Evernorth) trade 8–10x EBITDA. Health-IT businesses with Optum Insight's margin profile trade 12–20x. Care-delivery businesses trade 8–12x even in rough years. A plausible peer-average blended multiple for Optum is 10x; applied to 2025 adj OI that gives \~$121B of equity value, or \~$133/share of Optum alone.

You don't have to believe Optum is a SaaS franchise to see the gap. You have to believe it isn't worth 4x.

Why the market's 40% discount is wider than our 10%

Sum-of-segment EVs: $552B. Market-implied UNH enterprise value at $325: \~$349B. That's a \~37% discount the market is applying against our summed parts. Our override is 10%.

What the market is pricing into that gap:

• DOJ civil MA-billing investigation. Early-stage, financial exposure unquantified. Industry-precedent settlements range from a few billion to mid-teens; structural remedies (divestiture mandates) are a worse tail. This is the single largest unpriceable risk.
• Management and regulatory overhang. Ongoing CEO transition, FTC PBM scrutiny, CMS MA-coding tightening — layered on top of the DOJ case.
• Skepticism on Optum Health's adj-margin recovery and on whether Optum Insight is really a SaaS franchise or a commoditized IT business.

Why we stay at 10%:

1. $173B of intersegment revenue — 39% of gross revenue is internal. Optum Rx prescribes to UHC members; Optum Insight runs on UHC data; Optum Health sees UHC-affiliated patients. The "you'd rather own the pieces separately" discount is structurally bounded because the pieces are operationally entangled.
2. 15 years of integration. Optum was formed in 2011. The joint cost base, shared data assets, and cross-subsidization are fully baked in. A break-up remedy — even if DOJ pushed for one — would destroy real operating value, not unlock it.
3. UHC's DCF already prices the MCR and terminal-growth risk. Applying a 37% holding-company discount on top of a DCF that already discounts those cash flows double-counts.

A 20% discount — our market-stress fallback — gets you $446/share. Even the bearish reading inside our framework leaves ~35% upside from $325.

What you have to believe, ranked

Three claims carry the thesis. In decreasing order of impact:

1. DOJ does not produce a catastrophic financial or structural remedy. This is the only truly unpriceable claim. Base case: settlement in the $2–10B range with no divestiture mandate, consistent with prior MA-coding precedents. Bear case: $15B+ settlement plus forced structural separation, which would both widen the discount and destroy real operating value. A 30% incremental haircut off our fair value is the scenario we model; that's $494 → \~$345, roughly current price. Low conviction on the magnitude, moderate conviction that a total-blow-up remedy is unlikely given the prior whistleblower case trending toward dismissal.

2. UHC's MCR stabilizes, not necessarily improves. The model assumes a glide from 89.1% to 88.5% over three years. Management's 2026 guide is 88.8% ±50bps — which straddles our assumption on both sides. The thesis doesn't actually require MCR to drop 60bps; it only requires it not to drift further. Management has real levers here: prior-authorization reform (11% reduction already disclosed, 6.5M fewer requests annually), pool re-selection at renewal (membership guided down 1.2M in MA specifically), and premium repricing on 2027 bids. They will find a way. Medium conviction; Q1 2026 print on April 21 is the first hard test.

3. Optum segments trade closer to peer multiples as the overhang clears. Not "recover fully" — just "stop trading at distressed multiples." Optum Insight's 2025 recast adjusted margin is 21.7%; 2026 guide is 22.6%. That is SaaS-like, not commodity IT. Optum Rx margins are tracking peers. Optum Health is the weak link — 2026 guide is 2.4% operating margin, well below peers — but even that is above the 2025 crisis level. Medium conviction; re-rating is a multiples question more than an operational one.

We deliberately downgrade "OH margin recovery to 5.5%" from our prior ranking. Management guides to 2.4% in 2026, not 5.5%. If OH stays structurally lower, that's \~$30-40/share of our fair value at risk. Not thesis-breaking, but worth being honest about.

Margin of safety

Four concrete downside scenarios, each dollar-anchored:

Combined bear case — roughly half the value of our base case — gets you to \~$250/share. Against Friday's $325, that's $75 of downside and $170 of upside — a payoff ratio of about 2.3:1. At Monday's close the exact ratio will shift with the open, but unless UNH moves 10%+ on Monday the asymmetry holds.

That ratio is the investment. You are being paid roughly $2 to take $1 of quantifiable risk, on a name with management-acknowledged overhangs and a catalyst calendar that resolves most of the operational uncertainty over the next 2–4 quarters. The DOJ tail is the only piece that doesn't resolve on that timeline.

The secular risk nobody's modeling

One tail risk doesn't show up in any of the scenarios above because it hits the entire MCO sector, not UNH specifically: a structural decline in healthcare utilization from GLP-1 metabolic health gains plus AI-driven diagnostic efficiency. If the US medical cost curve genuinely bends in the back half of this decade, every managed-care insurer is a melting ice cube and every care-delivery business needs to be repriced.

This is low probability on a 3–5 year view but high consequence. It is the main reason we would size UNH at 2% rather than 5%. Not a thesis-killer, but a reason to keep the position modest until the secular picture is clearer.

What management said in the last print

Worth reading the 2026 guide alongside our assumptions:

• Revenue > $439B, group operating earnings > $24B, operating margin ~5.5% (up from 2025's 4.8%)
• MCR 88.8% ±50bps — brackets our 88.5% terminal
• Adjusted EPS > $17.75 (vs FY2025 adj $16.35)
• UHC earnings > $10.8B at 3.2% margin (vs 2025's 2.8% adjusted)
• Optum earnings > $13.2B at 5.1% margin (vs 2025's 4.5% adjusted)
• Operating cash flow > $18B
• Debt/capital trending to 40% target in 2026

Management is guiding to the range our model assumes. That is not a coincidence — our model uses management-disclosed trajectories — but it is evidence that the assumptions aren't out of sample.

What would make us wrong

• DOJ settles $15B+ or forces structural separation. We re-price the discount to 25–30% and fair value drops to $360-380.
• Q1 2026 MCR prints above 89.5% and management holds 2026 guide flat. Indicates prior-auth reform isn't moving the dial; re-underwrite.
• Q1 Optum Health operating margin negative ex-charges, or Optum Insight backlog contraction. Would validate the market's "Optum isn't worth what you say" view and compress our fair value by $30-50.
• GLP-1 utilization effect shows up in 2026 premium negotiations as structurally lower medical cost trend. This would be bullish for MCR short-term but bearish for the whole MCO sector's terminal value — and the market would lead the re-rating.

None of those are our base case. But they are the specific triggers to re-read the thesis against, not hand-wavy hedges.

Portfolio action

We will open UNH at 2% weight in our model portfolio at Monday, April 20, 2026 close — the first trading session after this post goes live — funded by selling SPY. We don't pre-announce an entry price because Monday's market will set it, not our framing. Two percent is deliberately small relative to our conviction in the base-case payoff, because:

1. The DOJ tail is genuinely unpriceable. Position sizing is our only defense.
2. The secular GLP-1/AI utilization risk affects the whole MCO sector, not just UNH.
3. We'd rather add on confirmation — a clean Q1 MCR, DOJ progress, an Optum Health margin stabilization — than top-tick the entry.

If the overhangs clear, we'd consider 3–4%. If MCR slips or the DOJ case materially escalates, we'd consider trimming toward 1% or closing. The current position + events-driven adds is the plan; buy-and-forget is not.

The current portfolio state is in the widget below and at /blog/portfolio.

The underlying valuation is generated by our sum-of-parts pipeline. Every segment's DCF inputs, every peer multiple, every override carries SEC-filing-grade provenance. The detail page at /ticker/UNH has the full trace including the 10-K quote excerpts behind each line item. We publish the work because the argument is the valuation, not the number at the bottom.

Update — Q1 2026 earnings (posted April 24, 2026)

UNH reported Q1 2026 on Tuesday April 21, three days after the original post went live. We are not revising what was written. This section scores the print against the specific falsifiers we named and updates the portfolio math. The underlying valuation has not been re-run.

What printed

The FY2026 adjusted EPS guide was raised $0.50 (from >$17.75 to >$18.25). Share repurchases pulled forward: at least $2B by end of Q2 rather than back-half weighted, explicitly justified by CFO Wayne DeVeydt citing "the deep intrinsic value discount at which our shares are currently trading."

Scoring against the post's specific falsifiers

We named three specific Q1 triggers in the original "What would make us wrong" section. All three resolved favorably:

1. "Q1 2026 MCR prints above 89.5% and management holds 2026 guide flat." Print: 83.9%, management raised the adjusted EPS guide by $0.50. Decisively avoided.
2. "Q1 Optum Health operating margin negative ex-charges." Print: +5.4% adjusted, +4.7% reported. Decisively avoided. Adj earnings of $1.3B were materially above sell-side expectations.
3. "Optum Insight backlog contraction." Print: revenue +1.9% YoY, backlog growth continued. Avoided, though margin compressed (see caveats below).

What the MCR number actually means (read this before getting excited)

The 83.9% headline is 530bps below FY2025's 89.1%, which sounds thesis-confirming. Management was explicit on the call about why it overstates the signal:

• "First half levels more than 250 basis points below the midpoint of our full year guidance, and second half levels more than 200 basis points above." The 83.9% is in line with the seasonal pattern against an ~88.8% FY midpoint, not a structural re-rating.
• Q1 "benefited modestly from seasonal dynamics, including lower-than-expected respiratory activity."
• Medical cost performance "driven primarily by net reserve development, better mix and enrollment dynamics in government programs" — prior-period reserve releases are non-recurring.
• "Underlying utilization trends remain broadly consistent with our expectations" — management is explicitly not calling a structural drop in medical cost trend. Medicare Advantage trend is still tracking to their 7–8% expectation with 10% pricing coverage.

The honest read: the print validates our thesis framing ("MCR stabilizes, doesn't get worse") rather than proving an aggressive improvement path. That's the bar we set and the bar that was cleared. Anyone reading the headline and modeling 83.9% into a terminal MCR is not reading the same transcript we are.

What didn't improve

• Optum Insight adj margin 15.3% vs 23.2% Q1 2025 — a ~790bps compression. Management attributed this to "slowly decommissioning old products that were not AI-based and reinvesting in those products through the AI investments." Back-half weighted recovery expected. Plausible but asks for patience.
• Optum Rx operating margin 3.3% vs 3.8% Q1 2025 — membership attrition at UHC is dragging script volume (383M vs 408M). Offset by specialty growth and 800 new client onboardings.
• Total medical membership 49.1M, down from 49.8M at YE2025. Intentional — management is "prioritizing margin recovery and product stability with a deliberate trade-off on membership growth." Consistent with 2026 guide, but means the top line is flat at best.

The DOJ silence

Not a single mention on the call, not one analyst question. Three months ago this was the dominant UNH topic. The DOJ case remains an open legal matter (referenced in the standard risk factors of the 8-K), but there was no incremental disclosure and no desk pushed for any. We flagged this as Category-3 unpriceable risk; nothing on Tuesday changed that assessment in either direction. Absence of news is not news, but it is a data point about market positioning.

Updated payoff math

The stock is up ~9% from our Monday April 20 entry ($323.48). The absolute gap to our $494 fair value is still meaningful, but the payoff ratio has compressed from 2.3:1 to roughly 1.4:1 because the cushion against the bear case is smaller. A more nuanced read: if the Optum Health margin beat makes our bear case less credible (we had assumed OH stuck at 2–3%, management just printed 5.4% adj and reiterated the 6–8% long-term target), the bear scenario probably shifts higher — maybe to $275–280 — restoring the payoff to the ~1.7:1 range. We are not formally re-running the model to chase that.

Portfolio action

No change. We hold the 2% UNH position opened Monday April 20 at $323.48.

The original post committed to adding on confirmation of a clean Q1 MCR, DOJ progress, or OH margin stabilization. Of those three, we got the first and the third; the DOJ situation is unchanged. That's enough to hold but not enough to scale up — at current $353 the asymmetry is real but materially less attractive than at $325, and chasing after a 9% move is exactly the behavior we said we'd avoid. We'd revisit sizing at the Q2 print (late July) with particular attention to:

• Whether H2 MCR creeps above the 91% top-of-guide band management implied (FY midpoint ~88.8% + 200bps)
• Whether Optum Health margin holds above 4% on a quarterly basis now that the one-time PYD boost is behind us
• Any DOJ case progression, in either direction

No re-running of the SOTP is warranted on this print alone. The thesis — UHC at fair value, Optum at distressed multiple, bounded holding-company discount — stands.

Q1 transcript source: FMP earnings-call-transcript API for UNH Q1 2026 (April 21, 2026). Press release and supplemental financial tables: UnitedHealth Group IR site.